Manoj Raghavan MBBS, PhD

Manoj has a major interest in the molecular and genetic basis of dysregulated haematopoiesis that characterizes myeloid malignancies. Increased understanding in this area has allowed development of new therapeutic strategies targeting underlying abnormalities within leukaemic cells. Manoj, together with Professor Craddock, is leading development of epigenetic therapies in patients with high risk myeloid malignancies. These studies, which involved close collaboration with Dr Sylvie Freeman, incorporate quantitation of leukaemic stem/progenitor populations with the aim of developing a novel biomarker of disease response.